格菲妥单抗为基础挽救治疗中国复发难治侵袭性B细胞淋巴瘤的真实世界疗效与安全性
该单中心观察性研究纳入64例接受格菲妥单抗为基础治疗的复发难治侵袭性B细胞淋巴瘤患者,56例可评估者完全缓解率和总缓解率分别为41.1%和78.7%,中位无进展生存和总生存未达到,估计1年无进展生存率和总生存率分别为61.3%和67.7%。非生发中心B细胞亚型患者无进展生存显著优于生发中心B细胞亚型(p=0.029),既往CAR-T治疗与较差无进展生存相关(p=0.022),既往双特异性抗体暴露不影响CAR-T制备或疗效,达到完全缓解者基线CD4+效应T细胞计数更高(p=0.04)且早期CD8+ T细胞扩增更高(p=0.02)。
要点
- 格菲妥单抗为基础方案在复发难治侵袭性B细胞淋巴瘤中完全缓解率41.1%、总缓解率78.7%。
- 非生发中心B细胞亚型无进展生存优于生发中心B细胞亚型(p=0.029)。
- 既往CAR-T治疗与较差无进展生存相关(p=0.022),既往双特异性抗体暴露不影响CAR-T制备或疗效。
核心结论
- 格菲妥单抗在复发难治侵袭性B细胞淋巴瘤中显示出持久疗效和可控安全性,治疗结局与T细胞功能状态密切相关,支持其作为CAR-T前有效桥接策略的潜力。
主要发现
- 56例可评估患者中完全缓解率和总缓解率分别为41.1%和78.7%,中位无进展生存和总生存未达到,估计1年无进展生存率和总生存率分别为61.3%和67.7%。
- 非生发中心B细胞亚型患者无进展生存显著优于生发中心B细胞亚型(p=0.029),既往CAR-T治疗与较差无进展生存相关(p=0.022)。
- 既往双特异性抗体暴露不影响CAR-T制备或疗效。
- 达到完全缓解者基线CD4+效应T细胞计数更高(p=0.04)且早期CD8+ T细胞扩增更高(p=0.02)。
临床怎么用
- 格菲妥单抗为基础方案可作为复发难治侵袭性B细胞淋巴瘤的挽救治疗选择,并可能作为CAR-T前的桥接策略。
- 治疗前可关注T细胞功能状态,基线CD4+效应T细胞计数和早期CD8+ T细胞扩增可能与完全缓解相关。
局限性
- 单中心观察性研究,样本量有限(64例),可评估患者56例。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Glofitamab, a CD20 × CD3 bispecific antibody, has demonstrated significant efficacy in relapsed or refractory (R/R) B-cell lymphomas. However, real-world evidence on its clinical performance and immunologic correlates, particularly in the context of chimeric antigen receptor T-cell (CAR-T) therapy, remains limited. This observational study included 64 patients with R/R aggressive B-cell lymphoma who received glofitamab-based therapy between February 2024 and December 2025 at the First Affiliated Hospital of Soochow University. The primary endpoint was complete response (CR) rate, whereas secondary endpoints included overall response rate (ORR), progression-free survival (PFS), overall survival (OS), and safety. We also analyzed the impact of prior bispecific antibody (BsAb) exposure on CAR-T cell manufacturing and efficacy and assessed the relationship between peripheral T-cell subsets and treatment outcomes. Among 56 evaluable patients, the CR and ORR were 41.1% and 78.7%, respectively. Median PFS and OS were not reached, with estimated 1-year PFS and OS rates of 61.3% and 67.7%. Patients with non-germinal center B-cell (non-GCB) subtype had significantly higher PFS than those with GCB subtype (p = 0.029), whereas prior CAR-T therapy was associated with poorer PFS (p = 0.022). Prior BsAb exposure did not affect CAR-T manufacture or efficacy. Immunophenotyping revealed that patients achieving CR had higher baseline CD4+ effector T-cell counts (p = 0.04) and higher early CD8+ T-cell expansion (p = 0.02). Overall, glofitamab demonstrated durable efficacy and a manageable safety profile in R/R aggressive B-cell lymphoma, with treatment outcomes closely associated with T-cell functional status, supporting its potential as an effective bridging strategy before CAR-T therapy.
引用
- Zhou J, Wang C, You T, et al. Real-World Efficacy and Safety of Glofitamab-Based Salvage Therapy in Chinese Patients With Relapsed or Refractory Aggressive B-Cell Lymphomas. Am J Hematol. 2026. PMID: 42108795. doi:10.1002/ajh.70359
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。